Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid by Fogh, Jens Rose et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative
LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid
Fogh, Jens Rose; Jacobsen, Anne-Marie; Nguyen, Tam T T N; Rand, Kasper D; Olsen, Line
Rørbæk
Published in:
Analytical and Bioanalytical Chemistry
DOI:
10.1007/s00216-020-02403-3
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Fogh, J. R., Jacobsen, A-M., Nguyen, T. T. T. N., Rand, K. D., & Olsen, L. R. (2020). Investigating surrogate
cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the
cerebrospinal fluid. Analytical and Bioanalytical Chemistry, 412, 1653-1661. https://doi.org/10.1007/s00216-020-
02403-3
Download date: 14. maj. 2020
RESEARCH PAPER
Investigating surrogate cerebrospinal fluid matrix compositions
for use in quantitative LC-MS analysis of therapeutic antibodies
in the cerebrospinal fluid
Jens Rose Fogh1,2 & Anne-Marie Jacobsen2 & Tam T. T. N. Nguyen1 & Kasper D. Rand1 & Line Rørbæk Olsen2
Received: 16 August 2019 /Revised: 17 December 2019 /Accepted: 10 January 2020
# The Author(s) 2020
Abstract
As quantitative analysis of biotherapeutics in cerebrospinal fluid (CSF) with LC-MS becomes increasingly widespread, there is a
need for method developments towards higher sensitivity. By using artificial CSF (aCSF) in the development phase, the
consumption of costly and sparsely available CSF can be limited. The aCSF compositions tested here were made from various
dilutions of bovine serum albumin (BSA) or rat plasma to mimic the total protein concentration found in CSF. Focusing on
monoclonal antibodies, the aCSF was spiked with human immunoglobulin (hIgG) and prepared with the bottom-up analysis
technique using LC-MS. Assuming that the composition of the aCSF would affect the digest, the response from aCSF matrices
was compared with CSF from rat, monkey, and dog in terms of estimated sample concentration and matrix effects. The samples
were spiked with hIgG in the range of 10 to 1000 ng/mL and volumes of 10 μL were transferred to sample preparation. The
results indicate that BSA dilutions from 300 to 2000 μg/mL and rat plasma dilutions of 0.5–2% provide the most accurate
concentration estimates when compared with rat CSF. 1000 μg/mL BSA did not produce significantly different concentration
estimates for 500 ng/mL samples when compared with CSF from rat, monkey, and dog, and can therefore be used as aCSF for
several different species.
Keywords Bioanalysis . Surrogate matrix . Liquid chromatography-mass spectrometry (LC-MS) . Monoclonal antibodies
(mAbs) . Cerebrospinal fluid (CSF)
Introduction
Within pharmaceutical research, there is considerable interest
in therapeutic antibodies, with 9 out of the 20 best-selling
drugs in 2018 being antibody-based [1]. Monoclonal antibod-
ies (mAbs) have several attractive features including high
specificity, longer half-life, and less side effects than tradition-
al small-molecule drugs [2]. It does come at a price, as the
sheer size and complexity of such mAbs can challenge
pharmacokinetic studies [3] and push analytical methods to
their limits. This is especially true for mAbs developed to treat
neurodegenerative diseases.
Examples of potential targets in neurodegenerative dis-
eases are amyloid β and tau proteins. In Alzheimer’s and
Parkinson’s disease, they form neurotic plaques containing
the aggregative amyloid β 1–42 amino acid form [4–6] and
neurofibrillary tangles with phosphorylated tau proteins [7, 8].
Treatment of targets like these with therapeutic antibodies
requires an estimation of mAb brain exposure to accurately
study the effects in preclinical species. Direct quantification of
brain material from experimental animals is often not feasible
because of the risk of blood contamination as only approxi-
mately 0.1% of macromolecules cross the blood-brain-barrier
(BBB) [9, 10]. Requirement of brain material also prevents the
method from being used in human studies and for repeated
extractions from live animals. An alternative approach to es-
timate mAb levels in the brain is to quantify levels in cerebro-
spinal fluid (CSF) [11]. The dominating challenge in early
drug research for quantitative analysis of mAb in CSF is the
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limited sample volume in preclinical species like mouse and
rat and the need for a suitable surrogate CSF matrix. A generic
screening method for mAb pharmacokinetics is needed for
simultaneous quantitation of different proteins in the same
small volume sample. Quantitative analysis using LC-MS of-
fers both multiplexing and high sensitivity for a generic meth-
od; however, the need for a suitable surrogate CSF matrix
remains.
Historically, quantitation of mAbs in CSF and plasma sam-
ples has been performed using ligand binding assay platforms
(LBA) [12–14]. LC-MS stands as a complimentary technique
to LBAs and offers the ability to quantify several proteins or
peptides simultaneously and with a high degree of specificity
[15]. In a preclinical setting with many different analytes of
interest, such as protein biomarkers and blood contamination
markers, it is beneficial with a short method development time
as can be obtained with LC-MS along with the option of
multiplexing [15]. LC-MS analysis of mAbs often uses the
bottom-up strategy where denatured mAb is digested to pro-
duce signature peptides for a sensitive and robust analysis
[16]. The sample preparation is influenced by matrix effect
from lipids, proteins, and salts and the protease must be opti-
mized to the total protein concentration in the sample for op-
timal digestion efficiency [17, 18]. This method is applied on a
routine basis for mAb in plasma samples [19–23], and though
CSF appears as a cleaner matrix with less proteins and lipids
(Table 1), some key differencesmust be noted, namely the low
sample volume and complicated sample collection. While ap-
proximately 15 mL CSF can be collected from humans during
a single sampling event [24], the situation is much different for
animal species commonly used in preclinical drug develop-
ment. The total volume of CSF in rats is around 90 μL and in
mice even less [25]. This greatly reduces the working volume
of CSF samples and makes sample collection a challenging
process with risk of blood contamination [26]. The limited
volume makes classical sample preparation such as pre-
concentration by immunopurification or solid-phase extrac-
tion less feasible and requires sensitive analysis methods to
detect drugs that only pass the BBB in low concentrations.
Often, it is also of value to have multiple readouts from CSF,
so disease biomarkers as well as mAbs can be quantified from
the same sample [24, 27, 28]. It is therefore important that a
viable surrogate matrix for CSF is found so optimized bottom-
up LC-MS methods can be developed for CSF matrices.
A standardized artificial CSF (aCSF) is needed as a surro-
gate matrix to develop and perform sensitive LC-MS methods
for CSF without the need of sacrificing several animals to
retrieve blank CSF. An aCSF must behave identically to
CSF with regard to digestion efficiency when exposed to the
bottom-up workflow. In addition, it must also mimic preven-
tion of any non-specific binding (NSB) of analytes, as NSB to
surfaces is an issue related to every process involving pipet-
ting and storage of peptides and proteins [32, 33]. Finally, LC-
MS ion suppression must be accounted for although the use of
a stable isotope–labeled (SIL) internal standard (ISTD) will
correct this to some degree. In short, an aCSF must affect all
stages of sample preparation and analysis to the same degree
as real CSF.
Various aCSF compositions have already been applied in
other labs and are summarized in Table 2. To our knowledge,
no prior studies have been conducted to systematically inves-
tigate how the composition of an aCSF will impact results
obtained from bottom-up LC-MS analysis of mAbs as
outlined above. The purpose of the present work is to address
this challenge and show which compositions of aCSF are
suitable for imitating real CSF samples in a bottom-up LC-
MS workflow for quantitative mAb analysis.
Materials and methods
Chemicals and reagents
CSF from all species was purchased from Seralab (UK) and
plasma was purchased from Cytotech (UK). SILu™Lite
SigmaMAb human immunoglobulin G1 (hIgG) standards,
SILu™Mab SIL hIgG, and bovine serum albumin (BSA)
were obtained from Sigma-Aldrich (MO, USA).
ProteinWorks eXpress Digest kit (Waters, MA, USA) was
used for the bottom-up workflow. The kit includes all reagents
used in the digestion workflow (Table 3) except for ultrapure
water (MQ) which is produced in-house on a Millipore
Synergy UV system (Merck, Germany). HPLC-grade aceto-
nitrile and ammonium bicarbonate were purchased from
Merck (Germany).
Calibration standards, control samples, and surrogate
matrices
The surrogate matrices were produced from either diluted rat
plasma or BSA. In total, 11 surrogate matrices were prepared
Table 1 Typical composition of human plasma and CSF [26, 29–31]
CSF Plasma
Proteins (μg/mL)
-Albumin
-Globulins
-Transferrin
-Fibrinogen
300–700
192
50
14
0.6
60,000–70,000
42,150
22,700
2600
2800
Lipids (μg/mL) 10–20 50,000
Na+ (mmol/L) 140–145 135–147
Cl− (mmol/L) 115–120 95–105
Glucose (μg/mL) 600 900
pH 7.31 7.41
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in 50 mM ammonium bicarbonate (AB50) for the following
concentrations: 20, 300, 600, 1000, 1400, 2000, and
10,000 μg/mL BSA and 0.5, 1, 2, and 5% rat plasma (in the
following, referred to as “surrogate matrix”).
Eight hIgG standards were prepared in the concentration
range 20–20,000 ng/mL in AB50 with 20 μg/mL BSA and
diluted 1:19 in surrogate matrix by liquid handling robot
(Hamilton Robotics, NV, USA) for a final calibration standard
range of 1–1000 ng/mL.
Manually prepared control and CSF samples were made by
spiking hIgG (prepared in AB50 with 20 μg/mL BSA) in
surrogate matrix or CSF in the ratio 1:9. Final samples were
stored at − 80 °C until use.
Instrumentation
All analytical work was carried out using Acquity UPLC sys-
tem (Waters, MA, USA) coupled with Xevo TQ-XS or Xevo
TQ-S triple quadrupole (Waters, MA). Separation was per-
formed using an Acquity CSH C18 Column, 130 Å, 1.7 μm,
2.1 × 100 mm (Waters, MA). Sample handling was performed
in protein LoBind plates and tubes (Eppendorf, Germany)
with low-retention pipette tips (Mettler Toledo, Switzerland).
Sample preparation
Quantitation by measuring selected tryptic peptides from
hIgG was done following the bottom-up approach as
outlined in Table 3. SILu™Mab was added at protein level
as ISTD in 20 μg/mL BSA to reduce NSB in the digestion
tubes. The hIgG samples stored in a freezer were then
thawed and added to the tubes. Samples were prepared
according to the instructions found in ProteinWorks with
some modifications to adjust for the reduced protein con-
centration in CSF compared with plasma (see Table 3).
Reduction and alkylation agents were used in 10 μL and
15 μL volumes respectively. Trypsin was diluted 1:1 in
digestion buffer and 15 μL was added to each sample.
Samples were denatured for 10 min at 80 °C and reduction
was performed at 60 °C for 20 min. The alkylation at
room temperature over 30 min was followed by digestion
for 2 h at 45 °C. The digestion was quenched by acidify-
ing the samples over 15 min at 45 °C and finally the
samples were centrifuged for 20 min at 5 °C at 1800
RCF. Seventy microliters of supernatant from each sample
was transferred to a 96-well plate and mixed with 40 μL
50:50 water:acetonitrile.
Table 2 A list of surrogate matrices used in other studies. Perfusion fluid is a term used for describing commercially available substitutes for CSF with
similar ionic composition and no protein content
Author or publication aCSF type Application
Lame et al. [34] 5% rat plasma in perfusion fluid Amyloid peptide quantitation
Dillen et al. [35] 0.15% bovine serum albumin in perfusion fluid Amyloid peptide quantitation
Hooshfar et al. [30] 0.5–17% rat plasma and perfusion fluid Small-molecule drug quantitation
Barthélemy et al. [36] 0.5% rat serum Tau protein quantitation
Oe et al. [37] 0.15% human serum albumin in perfusion fluid Amyloid peptide quantitation
Oeckl et al. [38] 340–1000 μg/mL human serum albumin in perfusion fluid Quantitation of synuclein species
Goda et al. [39] Perfusion liquid [40] Small-molecule drug quantitation
Table 3 Sample preparation as modified from the protocol found in the ProteinWorks kit
Step Experimental Purpose
Preparation 40 μL digestion buffer with 300 ng/mL SILu™Mab ISTD and
20 μg/mL BSA is added to each tube followed by 10 μL sample
Addition of internal standard and reduction of non-specific
binding
Denaturation Sample and internal standard is denatured for 10 min at 80 °C. Unfolding of the protein
Reduction Addition of 10 μL reduction agent and heating for 20 min at 60 °C Reduction of the cysteine bonds to make the protein accessible
to digestion
Alkylation Addition of 15 μL alkylation agent and covered from light for 30
min at room temperature
Alkylation of the thiol groups to prevent cysteine bonds from
reforming
Digestion Addition of 15 μL trypsin and heating for 2 h at 45 °C Cleavage of the protein to generate signature peptides
Quench Addition of 5 μL digestion inactivation agent and heating for 15
min at 45 °C followed by 20 min centrifugation at 1800 RCF at 4 °C
Decreasing the pH to quench the enzymatic activity of trypsin
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Chromatography and MS
The peptides were separated using 12-min gradient elution on
a UPLC system with a 20 μL sample loop. Mobile phase A
wasMQwater with 0.1% formic acid and mobile phase B was
acetonitrile with 0.1% formic acid (Table 4). Analysis was
performed in selected reaction monitoring (SRM) mode with
each signature peptide and its SIL equivalent being monitored
simultaneously. Signature peptides and their respective acqui-
sition settings are shown in Table 5 and represent different
polarity, sizes, and charge states. SIL peptides for ISTD were
of identical sequence and used the same method settings
(transitions found in the Electronic Supplementary Material,
ESM). All signature peptides have been found to be stable for
at least 24 h at 4 °C in a autosampler despite containing oxi-
dation prone amino acids like methionine and tyrosine. Peak
area was determined and normalized with ISTD using
TargetLynx quantitation software (Waters, MA). Further data
treatment and statistical analysis not supported by TargetLynx
were performed in GraphPad Prism 7 (GraphPad Software,
CA, USA).
Experiment setup
The setup was designed around three experiments in order to
investigate which surrogate matrices could be recommended
for use in quantitative analysis of CSF from preclinical spe-
cies. All the experiments were performed using the bottom-up
approach described in the “Sample preparation” section and,
except for the species difference evaluation, estimates were
based on the ALPAPIEK 419–654 signature peptide with
the remaining peptides in Table 5 used for validation.
First, the ion suppression and digestion efficiency were
investigated using the ISTD response from SIL peptides
added to the digestion tubes as intact protein in a relatively
large amount. From the procedure in Table 3, 40 μL 300 ng/
mL SIL standard was added to four replicates in the six dif-
ferent matrices plus CSF (rat) and five transitions were
monitored simultaneously. By summing the response from
each signature peptide normalized to CSF, the average matrix
effect from each surrogate matrix can be assessed. If any of the
surrogate matrices cause significant ion suppression or re-
duced digestion efficiency compared with CSF, it will result
in a lower signal for the SIL peptides.
The second experiment was designed to evaluate the accu-
racy and precision of QC samples in different surrogate ma-
trices to determine if factors other than ion suppression and
digestion efficiency could affect the estimates. Nine different
surrogate matrices were spiked with hIgG at 3 levels (10, 100,
and 1000 ng/mL) in 4 replicates and estimated using one cal-
ibration curve in 1000 μg/mL BSA. Spiked rat CSF was used
as a reference.
The last experiment evaluated species differences using a
surrogate matrix of 1000 μg/mL to estimate concentrations of
QC samples spiked into CSF from dog, rat, and monkey. This
experiment would determine if an aCSF could be used for
multiple species and provide an accurate estimate. QC samples
of 500 and 1000 ng/mL in 4 replicates were estimated using
GPSVFPLAPSSK 418–506 and TTPPVLDSDGSFFLYSK
937–836 signature peptides to reduce interference from endog-
enous peptides.
Results and discussion
Calibration curves for quantitation
Human IgG is considered a suitable analyte for evaluation of
aCSF as it produces stable signature peptides of different sizes
and hydrophobicity (chromatogram shown in ESM) that can
be affected differently by the tested matrices. The hIgG con-
centration was estimated using calibration curves made in
1000 μg/mL BSA. The statistical data from the linear regres-
sion on each fragment is shown in Table 6. Selected peptides
allowed calibration ranges of 1–1000 ng/mL with no data
points deviating more than 20% from the model. Rat CSF
and BSA show no interference with the signature peptides in
Table 5 as tested experimentally (see ESM) and with a
BLASTsearch. The ALPAPIEK 419–654 peptide was chosen
for quantitation of all samples (unless otherwise stated) while
the other peptides were used for validation. In general, the
method performed well and allowed reliable quantitation of
samples with 10 ng/mL in 10 μL volumes of rat CSF.
Matrix effect on internal standard response
Six surrogate matrices covering a broad range of protein con-
tent were investigated for their matrix effect on the ISTD
signal. Each bar displayed in Fig. 1 represents the response
from all signature peptides normalized to CSF (= 100%). By
using multiple transitions from peptides with different
Table 4 Time points and compositions for the UPLC gradient used for
all experiments. 0.1% formic acid was added to both mobile phases
Time (min) A (H2O) (%) B (ACN) (%)
0 98 2
2 98 2
8 70 30
8.5 10 90
9.5 10 90
10 98 2
12 98 2
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properties, the average matrix effect can be assessed. A
one-way ANOVA determined that two of the matrices pro-
duced significantly lower responses (p < 0.05) than ob-
served in CSF (mean peak areas and p values are shown
in ESM). The two matrices, 10,000 μg/mL BSA and 5%
plasma (3000 μg/mL total protein), had the highest protein
content of the tested matrices. It is likely that the reduced
response was caused either by ion suppression or by de-
creased digestion efficiency; hence, the high protein con-
centration matrices cannot be recommended to use as a
surrogate for CSF. However, the 10,000 μg/mL BSA ma-
trix was analyzed further to determine if ISTD is capable of
correcting the reduced signal observed. The remaining ma-
trices produced similar responses so any variation ob-
served for the hIgG analyte in the following experiments
was likely caused by factors other than ion suppression and
digestion efficiency. The 1000 μg/mL BSA matrix showed
the closest resemblance to rat CSF so this was chosen as
the default calibration curve.
Comparison of aCSF compositions
Nine different surrogate matrices were evaluated by spiking
with three levels of hIgG (10, 100, 1000 ng/mL) and compar-
ing the estimates with similar samples in rat CSF. The results,
including coefficient of variation and accuracy, are listed in
Table 7. The majority of the spiked samples was within ± 20%
accuracy relative to the 1000 μg/mL BSA calibration curve
and is therefore considered to show acceptable performance as
surrogate matrices. One exception was the 20 μg/mL BSA
matrix with less than 80% accuracy which is therefore consid-
ered unsuitable as a surrogate matrix. The total content of
protein in the 20 μg/mL BSA is considerably lower than that
in the other tested matrices and the lower response observed in
this matrix may possibly be due to increased NSB during
sample handling and preparation. The ISTD signal from the
same samples was not affected, which indicates that the loss
must have occurred during storage and handling prior to the
bottom-up method.
The range of total protein content in the remaining ma-
trices (300–10,000 μg/mL protein) is likely to cover bio-
logical variations of real CSF samples. Even the
10,000 μg/mL BSA matrix provided similar accuracy as
the other matrices and could work as an aCSF, but it should
be noted that the overall decreased signal caused by the
large amount of protein can decrease sensitivity and in-
crease column wear. Also, it was only possible to achieve
this accuracy because a SIL signature peptide was avail-
able. A novel biotherapeutic with a unique sequence can-
not rely on available SIL signature peptides. These results
demonstrate the importance of the total protein concentra-
tion in the matrix since this will significantly affect the
estimated concentration of a hIgG analyte. The protein
content needs to be above a level where NSB is avoided
Table 5 Signature peptides with their respective settings as used in SRM for the quantitation of hIgG. Position is referring to the SILu™Lite hIgG
sequence at the constant region of the heavy chain (HC). The ISTD equivalents can be found in the ESM
Peptide Amino acid position Precursor (m/z) Fragments (m/z) Dwell time (ms) Collision energy (eV) Cone voltage (V)
ALPAPIEK 331–338 HC 419.76 654.38
486.29
59
59
11
20
20
20
DTLMISR 253–259 HC 418.22 506.28 59 17 20
GPSVFPLAPSSK 126–137 HC 593.83 699.40 80 21 40
VVSVLTVLHQDWLNGK 306–321 HC 603.34 805.44 68 20 20
TTPPVLDSDGSFFLYSK* 397–413 HC 937.46 836.42 16 20 20
*Only used when comparing different species because of low interference from endogenous peptides
Table 6 Key data for the
calibration curves generated and
used to estimate sample
concentrations. SIL versions of
the same peptides were used as
internal standard for all
experiments
Peptide Fragment (m/z) Calibration curve
range (ng/mL)
Weighting Linear fit (r2) Slope
ALPAPIEK 654.38
486.29
1–1000
1–1000
1/x
1/x
0.9996
0.9999
0.00152
0.00148
DTLMISR 506.28 10–1000 1/x 0.9992 0.00204
GPSVFPLAPSSK 699.40 50–1000 1/x 0.9974 0.00144
VVSVLTVLHQDWLNGK 805.45 50–1000 1/x 0.9997 0.00153
TTPPVLDSDGSFFLYSK 836.42 10–1000 1/x 0.9990 0.00128
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but below a level where it does not affect digestion effi-
ciency or cause ion suppression in the MS analysis as seen
in Fig. 1. Seemingly, CSF contained enough protein to
prevent any observable NSB of the hIgG analyte. The co-
efficient of variation was below 10% for 28 out of the 32
replicates and provides a good measure of the robustness
of the bottom-up method used.
Although 300–10,000 μg/mL BSA and 0.5–2% plasma
all performed well as a surrogate matrices for CSF, there
are some considerations to take into account. BSA from a
standardized production is expected to give less batch
variation due to the relatively homogenous content.
There is less chance of the matrix containing any proteins
or proteases that can affect the analyte of interest which
assures a similar effect across different analytes. Diluted
plasma is under influence from the species of origin, diet,
and other factors [41] and has different protein concentra-
tions and compositions across individual donors.
However, diluted plasma consists of a large variety of
proteins and other components and can behave more re-
alistically with regard to interferences during analysis or,
if needed, immunocapture. In either case, the biological
matrix must be examined for any protein sequence over-
lap with the analyte or identical fragmentation patterns
during analysis by MS. For a more general purpose than
hIgGs, BSA has the advantage that the risk of finding
endogenous peptides or proteins is low, and therefore,
BSA may be well suited for, e.g., biomarker quantitation
using LC-MS.
Comparison of aCSF with CSF from preclinical species
Two levels of hIgG in CSF from three species were estimated
using a single surrogate matrix. Results shown in Fig. 2 are
based on peptides GPSVFPLAPSSK (GPSV) and
TTPPVLDSDGSFFLYSK (TTPP) to provide common signa-
ture peptides for all three species. The results show that
1000 μg/mL BSA performs well as aCSF for rat, dog, and
monkey by producing estimates within ± 20% of the predicted
levels. Inter-species difference was expected due to the differ-
ent CSF compositions but the aCSF was able to cover these
with 20% margin. Remaining peptides from Table 5 were
excluded for testing because of experimentally observed inter-
ference (see ESM). For the same reason, it was not possible to
estimate concentrations below 500 ng/mL using a common
signature peptide as interference became significant. It should
be noted that lower levels of hIgGwere correctly estimated for
all species by using different signature peptides optimized for
each species.
Conclusion
Our findings reveal that in a bottom-up LC-MS analysis of
a model mAb (hIgG), it is recommended to use a BSA
solution in the range of 300 to 2000 μg/mL to replicate
the analytical response in rat CSF. Plasma dilutions of 0.5
to 2% can also be used as an adequate aCSF matrix; how-
ever, the BSA matrix likely offers less variation and less
chance of interference from endogenous proteins. The
highest protein concentration of 10,000 μg/mL BSA also
provided similar accuracy to other matrices, but the signal
intensities were noticeably lower which can be expected to
decrease sensitivity. Matrices with particularly low protein
concentration underestimated hIgG levels when compared
with real CSF and must be avoided.
The bottom-up LC-MSmethod used here for quantification
of mAbs provides the ability to accurately measure 10 ng/mL
hIgG in sample volumes of 10 μL rat CSF or aCSF with no
additional sample cleanup after digestion. The investigated
aCSF could be applied to species other than rat, as shown with
standards prepared in 1000μg/mLBSA that was able to quan-
tify hIgG in CSF from rat, dog, and monkey within 20% of the
true concentration. It is highly plausible that other species can
be included as the investigated matrices covered a large range
of protein contents (20–10,000 μg/mL) to account for any
biological variation within or between species. We hypothe-
size that the identified aCSF compositions that yielded reason-
able results for mAb analysis in the current study may also be
useful for quantitative analysis of other biotherapeutics or
protein biomarkers in CSF where digestion efficiency and
NSB are important factors.
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Fig. 1 Comparison of the response from internal standard in 6 different
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Mean values significantly different from those obtained in the CSFmatrix
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Table 7 Various aCSF
compositions spiked with hIgG
(n = 4) to determine the effect on
the response. The estimation is
performed using a calibration
curve in 1000 μg/mL BSA.
Concentrations estimates of hIgG
are based on theALPAPIEK 419–
654 peptide fragment with 20 μL
injections. The total protein
amount is derived from theoreti-
cal values
Matrix Total protein in
matrix (pr. 10 μL)
QC conc
(ng/mL)
Mean cal.
conc (ng/mL)
% CV Mean accuracy (%)
Rat CSF 3–7 μg 10
50
100
500
1000
10.0
56.5
127.2
493.9
1103.0
9.0
4.6
6.6
4.3
2.6
100
113
127
98
110
20 μg/mL BSA 0.2 μg 10
100
1000
7.0
73.4
786.6
8.6
5.1
8.3
70
73
79
300 μg/mL BSA 3 μg 10
100
1000
8.2
82.0
865.2
9.0
1.7
5.9
82
82
87
600 μg/mL BSA 6 μg 10
100
1000
10.5
96.5
945.7
12.6
4.8
8.5
105
96
95
1000 μg/mL BSA 10 μg 10
100
1000
8.6
94.1
957.6
9.5
3.4
5.0
86
94
96%
1400 μg/mL BSA 14 μg 10
100
1000
9.3
83.6
996.8
8.1
2.4
8.8
93
84
100
2000 μg/mL BSA 20 μg 10
100
1000
9.4
98.8
1036.4
15.1
3.8
6.1
94
99
104
10000 μg/mL BSA 100 μg 10
100
1000
9.8
88.3
1057.6
14.80
5.32
3.30
98
88
106
0.5% rat plasma 3 μg 10
100
1000
8.2
86.5
979.3
8.8
11.8
5.3
82
87
98
2% rat plasma 12 μg 10
100
1000
12.7
102.8
1096.8
6.3
4.4
5.4
127
103
110
500 ng/mL
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